Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal.

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

CALGB (Alliance): A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer Wolf Köster, MD, Andrea Heider, MD, Norbert.

Utility of 18F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation Andrea L.H. Arnett, MD, PhD, Kenneth.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Jos A. Stigt, MD, PhD, Richard Vossenkaul, MD, Wouter H

Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status Young Joo Lee, MD, Heung Tae Kim, MD,

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.

Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma Ho Yun Lee, MD, PhD, So Won Lee, MD, Kyung.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer Masatsugu Hamaji, MD, Mark S. Allen,

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Randomized Phase II Study of Palifermin for Reducing Dysphagia in Patients Receiving Concurrent Chemoradiotherapy for Locally Advanced Unresectable Non-small.

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma Ho Yun Lee, MD, PhD, So Won Lee, MD, Kyung.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

A Randomized Phase II Trial of Two Schedules of Docetaxel in Elderly or Poor Performance Status Patients with Advanced Non-small Cell Lung Cancer Rogerio.

Elderly Former Smoker with HRAS Mutant Non–Small-Cell Lung Cancer

Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after.

Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter.

Outcomes of Mediastinoscopy and Surgery with or without Neoadjuvant Therapy in Patients with Non-small Cell Lung Cancer Who are N2 Negative on Positron.

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases Silvia Novello, MD, Carlos Camps, MD, Francesco.

Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304) Gregory A. Otterson,

A Case of Nontuberculous Mycobacteria Highly Suspected as Lung Cancer Invading the Aortic Arch Tadashi Umehara, MD, Masaya Aoki, MD, PhD, Aya Harada,

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43– 9006) in Previously Treated Non–Small-Cell Lung Cancer Patients: Eastern.

Matthew Reichert, MD, Eric S. Bensadoun, MD

The Role of Histology with Common First-line Regimens for Advanced Non-small Cell Lung Cancer: A Brief Report of the Retrospective Analysis of a Three-arm.

Nicholas Trakul, MD, PhD, Jeremy P

DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Pulmonary Resection for Metastases from Colorectal Cancer

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy.

Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC Francesco Gelsomino, MD, Valentina.

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104 Ramaswamy Govindan, MD, Xiaofei.

Linda L. Garland, MD, Kari Chansky, MS, Antoinette J

Primary Small Cell Carcinoma of the Esophagus

Metastatic Lung Cancer to the Pancreas

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

Phase I/II Study of Vinorelbine and Exisulind as First-Line Treatment of Advanced Non- small Cell Lung Cancer in Patients at Least 70 Years Old: A Wisconsin.

A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Jamie E. Chaft, MD, Camelia S. Sima, MD, MS, Michelle S

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Farhood Farjah, MD, MPH, David R. Flum, MD, MPH, Scott D

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive.

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma Maryam B. Lustberg, MD, Tanios Bekaii-Saab, MD, Donn Young, PhD, Gregory Otterson, MD, William Burak, MD, Abbas Abbas, MD, Barbara McCracken-Bussa, BA, Mark E. Lustberg, MD, PhD, Miguel A. Villalona-Calero, MD Journal of Thoracic Oncology Volume 5, Issue 5, Pages 713-718 (May 2010) DOI: 10.1097/JTO.0b013e3181d7776d Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 A, Plot of percentage change in computed tomography (CT) tumor size by arm. Individual percentage change in tumor size by CT scan according to the treatment arm (n = 30). B, Plot of percentage change in standard uptake values (SUV) by arm. Individual percentage change in tumor SUV by positron emission tomography according to the treatment arm (n = 38). Two additional patients with progressive disease because of new metabolic lesions were not included. Journal of Thoracic Oncology 2010 5, 713-718DOI: (10.1097/JTO.0b013e3181d7776d) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 A, Kaplan-Meier plots of progression free survival by percentage change in standard uptake values (SUV). Kaplan-Meier plots showing progression-free survival according to percent decreases in SUV >25% and <25%. There is a statistically significant difference between patients with and without a metabolic response (P = 0.02). B, Kaplan-Meier plots of overall survival by percentage change in SUV. Kaplan-Meier plots showing overall survival according to percent decreases in SUV >25% and <25%. There is a statistically significant difference between patients with and without a metabolic response (P = 0.006). Journal of Thoracic Oncology 2010 5, 713-718DOI: (10.1097/JTO.0b013e3181d7776d) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions